Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantern Pharma Inc. on June 16, 2020, covering events occurring between June 11, 2020, and June 15, 2020. The filing primarily documents corporate actions taken in connection with the company's Initial Public Offering (IPO), including stock splits, equity conversions, and amendments to its Certificate of Incorporation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and equity structure changes.
Material Changes
- Stock Split: A 1.74-for-1 forward stock split became effective on June 11, 2020.
- Preferred Stock Conversion: Effective June 15, 2020, all outstanding Series A Preferred Stock was converted into an aggregate of 2,438,851 shares of common stock. This conversion was exempt from registration under Section 3(a)(9) of the Securities Act.
- Equity Grants: On June 15, 2020, options to purchase 306,743 shares of common stock were granted to ten directors, officers, or employees. The exercise price was set at $15.00 per share under the 2018 Equity Incentive Plan. These issuances were exempt from registration under Section 4(a)(2) of the Securities Act.
- Capital Structure Amendment: An Amended and Restated Certificate of Incorporation became effective on June 15, 2020. This increased authorized capital stock to 26,000,000 shares (25,000,000 common and 1,000,000 preferred) and eliminated the designation of Series A preferred stock.
Guidance, Outlook, and Risks
The filing confirms the closing of the company's IPO via a press release issued on June 15, 2020. No specific financial guidance, forward-looking outlook, or discussion of risks and contingencies is provided within the text of this 8-K. The press release referenced in Item 8.01 is furnished for informational purposes only and is not deemed "filed" under the Exchange Act.
Investor Verification Checklist
- Verify the final share count and capitalization table following the 1.74-for-1 stock split and Series A conversion.
- Confirm the terms of the 306,743 stock options granted, including vesting schedules and the $15.00 exercise price.
- Review the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1(v)) for details on the new authorized share limits.
- Examine the IPO press release (Exhibit 99.1) for details on the offering size, underwriters, and net proceeds, which are not detailed in this 8-K.